The USFDA has recently approved letibotulinumtoxin A for treating moderate-to-severe glabellar lines in adults. Letibotulinumtoxin A can temporarily improve the appearance of moderate-to-severe glabellar lines. The safety and efficacy of letibotulinumtoxin A was evaluated in three phase 3 clinical trials.
Clinical evidence Based on the Glabellar Line Scale score, 47%, 49%, and 65% of patients were treated successfully in three clinical trials four weeks after initiating treatment. Dosage and administration Recommended dose – 0.1 mL Intramuscular injection into five sites – Two injections in each corrugator muscle and one injection in the procerus muscle Contraindications Hypersensitivity to any botulinum toxin preparation Infections at the injection sites Warnings and precautions Letibotulinumtoxin A can spread toxin effects and cause swallowing and breathing difficulties, which can…
